Research in motion: the enigma of Parkinson's disease pathology spread

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Nature Reviews Neuroscience

• Publication date

  2008-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrn2477PMID 18769444
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death.

  2010cited by this paper
• Oxidative Stress in Parkinson's Disease

  2008cited by this paper
• Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration.

  2008cited by this paper
• Controversies over the staging of α-synuclein pathology in Parkinson’s disease

  2008cited by this paper
• A critical reappraisal of current staging of Lewy-related pathology in human brain

  2008cited by this paper
• Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein.

  2008cited by this paper
• Invited Article: Nervous system pathology in sporadic Parkinson disease

  2008cited by this paper
• Non‐motor symptoms in Parkinson’s disease

  2008cited by this paper
• Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease

  2008cited by this paper
• Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease

  2008cited by this paper
• alpha-Synuclein pathology in the neostriatum in Parkinson's disease.

  2008cited by this paper
• α-Synuclein pathology in the neostriatum in Parkinson’s disease

  2008cited by this paper
• Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation

  2008cited by this paper
• Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years

  2008cited by this paper
• Review: Familial Parkinson's disease – genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease

  2008cited by this paper
• Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication

  2007cited by this paper
• Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease

  2007cited by this paper
• Non-motor Symptoms of Parkinson's Disease

  2007cited by this paper
• GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease.

  2007cited by this paper
• Oxidative stress‐induced phosphorylation, degradation and aggregation of α‐synuclein are linked to upregulated CK2 and cathepsin D

  2007cited by this paper
• Inflammation as a causative factor in the aetiology of Parkinson's disease

  2007cited by this paper
• Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.

  2007cited by this paper
• Cognitive Impairment in Parkinson’s Disease and Dementia with Lewy Bodies: A Spectrum of Disease

  2007cited by this paper
• Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation

  2007cited by this paper
• Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?

  2007cited by this paper
• Exogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host

  2006cited by this paper
• Convergence of Heat Shock Protein 90 with Ubiquitin in Filamentous α-Synuclein Inclusions of α-Synucleinopathies

  2006cited by this paper
• Understanding the molecular causes of Parkinson's disease.

  2006cited by this paper
• Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease.

  2006cited by this paper
• Amino acid sequence motifs and mechanistic features of the membrane translocation of α‐synuclein

  2006cited by this paper
• Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies.

  2006cited by this paper
• Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.

  2006cited by this paper
• Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies

  2005cited by this paper
• α-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease

  2005cited by this paper
• Intravesicular Localization and Exocytosis of α-Synuclein and its Aggregates

  2005cited by this paper
• Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: 'permissive templating' as a general mechanism underlying neurodegeneration.

  2005cited by this paper
• Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium

  2005cited by this paper
• Reactive Macrophages Increase Oxidative Stress and Alpha-Synuclein Nitration During Death of Dopaminergic Neuronal Cells in Co-Culture: Relevance to Parkinson’s Disease

  2005cited by this paper
• Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications

  2004cited by this paper
• Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications.

  2004cited by this paper
• Temporal pattern of host responses against intrastriatal grafts of syngeneic, allogeneic or xenogeneic embryonic neuronal tissue in rats

  2004cited by this paper
• α‐Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma

  2003cited by this paper
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper
• Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen

  2003cited by this paper
• Oxidative stress in Parkinson's disease

  2003cited by this paper
• Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein

  2002cited by this paper
• Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease?

  2002cited by this paper
• Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein.

  2002cited by this paper
• Greenfield's Neuropathology

  2002cited by this paper
• Induction of Neuronal Cell Death by Rab5A-dependent Endocytosis of α-Synuclein*

  2001cited by this paper
• Alpha-synuclein and the Lewy body disorders.

  2001cited by this paper
• Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects

  2000cited by this paper
• Neuropathology of fetal nigra transplants for Parkinson's disease.

  2000cited by this paper
• Neurotrophic factors in Alzheimer's and Parkinson's disease brain.

  2000cited by this paper
• α‐Synuclein Up‐Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTP

  2000cited by this paper
• Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects.

  2000cited by this paper
• Sequential bilateral transplantation in Parkinson's disease: effects of the second graft.

  1999cited by this paper
• Dopamine D2‐type agonists protect mesencephalic neurons from glutamate neurotoxicity: Mechanisms of neuroprotective treatment against oxidative stress

  1998cited by this paper
• Excitotoxicity and nitric oxide in parkinson's disease pathogenesis

  1998cited by this paper
• a-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies (ubiquitinysarkosyl-insoluble filamentsyimmunoelectron microscopy)

  1998cited by this paper
• Ageing changes in the transplants of fetal substantia nigra grafted to striatum of adult rat.

  1991cited by this paper
• Electrophysiological characteristics of cells within mesencephalon suspension grafts

  1991cited by this paper
• Host afferents into intrastriatal transplants of fetal ventral mesencephalon.

  1989cited by this paper
• Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

  1988cited by this paper
• Electrophysiological demonstration of host cortical inputs to striatal grafts.

  1987cited by this paper
• NEUROPATHOLOGY

  1954cited by this paper
• Journal of Neuroinflammation Interleukin-1 Mediates Alzheimer and Lewy Body Pathologies

  year unknowncited by this paper

• C1q-dependent clearance of alpha-synuclein allows macrophages to transiently limit enteric synucleinopathy in male mice

  2026cites this paper
• Protein quality control systems in neurodegeneration – culprits, mitigators, and solutions?

  2025cites this paper
• Aggregation and Propagation of α‐Synuclein in Parkinson's Disease: A Bibliometric Perspective

  2025cites this paper
• Secondary nucleation of α-Synuclein drives Mitochondria dysfunctions and Lewy body formation in Parkinson’s Disease

  2025cites this paper
• α-Synuclein pathology as a target in neurodegenerative diseases

  2024cites this paper
• Biperiden Hydrochloride/β -Cyclodextrins supramolecular system and its cytotoxicity against lung adenocarcinoma cells

  2023cites this paper
• Recent advances in natural products targeting α-synuclein aggregation or clearance in Parkinson's disease

  2023cites this paper
• Ca2+ signalling: A common language for organelles crosstalk in Parkinson's disease.

  2023cites this paper
• Human iPSC-derived midbrain organoids functionally integrate into striatum circuits and restore motor function in a mouse model of Parkinson's disease

  2023cites this paper
• Alpha-synuclein oligomers activate NFAT proteins modulating synaptic homeostasis and apoptosis

  2023cites this paper
• On-Tissue Chemical Derivatization for Comprehensive Mapping of Brain Carboxyl and Aldehyde Metabolites by MALDI–MS Imaging

  2023cites this paper
• The Zebrafish Model as a New Discovery Path for Medicinal Plants in the Treatment of Parkinson's Disease.

  2023cites this paper
• The alpha-synuclein oligomers activate nuclear factor of activated T-cell (NFAT) modulating synaptic homeostasis and apoptosis

  2023cites this paper
• Development of Small Molecules Targeting α-Synuclein Aggregation: A Promising Strategy to Treat Parkinson’s Disease

  2023cites this paper
• Complement C1q-dependent engulfment of alpha-synuclein induces ENS-resident macrophage exhaustion and accelerates Parkinson’s-like gut pathology

  2023cites this paper
• The gut microbiome as a factor in the development of Parkinson's disease

  2023cites this paper
• The cervical lymph node contributes to peripheral inflammation related to Parkinson’s disease

  2023cites this paper
• Alpha-synuclein oligomers activate nuclear factor of activated T-cells (NFAT) modulating apoptosis and synaptic homeostasis

  2023cites this paper
• Targeting α-Synuclein in Parkinson's Disease by Induced Pluripotent Stem Cell Models

  2022cites this paper
• New Frontiers on ER Stress Modulation: Are TRP Channels the Leading Actors?

  2022cites this paper
• Corticospinal suppression underlying intact movement preparation fades in late Parkinson's disease

  2022cites this paper
• The Hidden Cell-to-Cell Trail of α-Synuclein Aggregates.

  2022cites this paper
• ReviewEmerging Therapeutic Strategies for Parkinson's Disease and Future Prospects: A

  2022cites this paper
• Corticospinal Suppression Underlying Intact Movement Preparation Fades in Parkinson's Disease

  2022cites this paper
• Unique Lewy pathology in myotonic dystrophy type 1

  2022cites this paper
• Emerging Therapeutic Strategies for Parkinson’s Disease and Future Prospects: A 2021 Update

  2022cites this paper
• Better Outcomes with Intranigral versus Intrastriatal Cell Transplantation: Relevance for Parkinson’s Disease

  2022cites this paper
• Neuropathology of α‐synuclein in Parkinson's disease

  2022cites this paper
• Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight.

  2021cites this paper
• Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes

  2021cites this paper
• Surgical treatment of Parkinson disease and other movement disorders

  2021cites this paper
• Gut and brain profiles that resemble pre-motor and early-stage Parkinson's disease in methamphetamine self-administering rats.

  2021cites this paper
• References

  2021cites this paper
• Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease

  2021cites this paper
• The Origins of the Protein Spread in Parkinson's Disease

  2021cites this paper
• Assessment of the Telomere Length and Its Effect on the Symptomatology of Parkinson’s Disease

  2021cites this paper
• Preclinical models based on endogenous neurotoxins

  2021cites this paper
• Activated microglia facilitate the transmission of α-synuclein in Parkinson's disease.

  2021cites this paper
• Nanotherapeutics approaches for targeting alpha synuclien protein in the management of Parkinson disease

  2021cites this paper
• Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies

  2021cites this paper
• Potential roles of functional bacterial amyloid proteins, bacterial biosurfactants and other putative gut microbiota products in the etiopathogeny of Parkinson’s Disease

  2021cites this paper
• The Evolving Landscape of Exosomes in Neurodegenerative Diseases: Exosomes Characteristics and a Promising Role in Early Diagnosis

  2021cites this paper
• FRET-based Tau seeding assay does not represent prion-like templated assembly of Tau filaments

  2020cites this paper
• From Synaptic Protein to Prion: The Long and Controversial Journey of α-Synuclein

  2020cites this paper
• Studies on the Etiology of Parkinson’s disease

  2020cites this paper
• Cerebral sterile inflammation in neurodegenerative diseases

  2020cites this paper
• Trans-synaptic and retrograde axonal spread of Lewy pathology following pre-formed fibril injection in an in vivo A53T alpha-synuclein mouse model of synucleinopathy

  2020cites this paper
• Cellular pathophysiology and basal ganglia dysfunction in Parkinson's disease: an overview

  2020cites this paper
• Impaired Phasic Discharge of Locus Coeruleus Neurons Based on Persistent High Tonic Discharge—A New Hypothesis With Potential Implications for Neurodegenerative Diseases

  2020cites this paper
• Midbrain Dopaminergic Neuron Development at the Single Cell Level: In vivo and in Stem Cells

  2020cites this paper
• Co-administration of TiO2-nanowired dl-3-n-butylphthalide (dl-NBP) and mesenchymal stem cells enhanced neuroprotection in Parkinson's disease exacerbated by concussive head injury.

  2020cites this paper
• Role of Long Noncoding RNAs in Parkinson's Disease: Putative Biomarkers and Therapeutic Targets

  2020cites this paper
• The gut-brain axis in the pathogenesis of Parkinson’s disease

  2019cites this paper
• Prions: Current Progress in Advanced Research

  2019cites this paper
• Nanobiotechnology in Neurodegenerative Diseases

  2019cites this paper
• Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments

  2019cites this paper
• The multiple roles of exosomes in Parkinson's disease: an overview

  2019cites this paper
• Dementia with Lewy bodies: an update and outlook

  2019cites this paper
• Inactivation Methods for Prions.

  2019cites this paper
• Genetically engineered stem cell‐derived neurons can be rendered resistant to alpha‐synuclein aggregate pathology

  2019cites this paper
• Neural connectivity predicts spreading of alpha-synuclein pathology in fibril-injected mouse models: Involvement of retrograde and anterograde axonal propagation

  2019cites this paper
• Prion-like mechanisms in Parkinson Disease

  2019cites this paper
• Neurodegeneration and contralateral α-synuclein induction after intracerebral α-synuclein injections in the anterior olfactory nucleus of a Parkinson’s disease A53T mouse model

  2019cites this paper
• Design of LRRK2 inhibitors using a CHK1-derived crystallographic surrogate

  2019cites this paper
• Natural products: An emerging tool in parkinson’s disease therapeutics

  2019cites this paper
• Pulmonary function and cardiorespiratory fitness in idiopathic Parkinson's disease

  2018cites this paper
• Special issue “Parkinson’s disease”

  2018cites this paper
• A refined concept: &agr;‐synuclein dysregulation disease

  2018cites this paper
• Non‐cell‐autonomous actions of &agr;‐synuclein: Implications in glial synucleinopathies

  2018cites this paper
• Alpha Synuclein and Parkinson’s Disease

  2018cites this paper
• Sensing α‐Synuclein From the Outside via the Prion Protein: Implications for Neurodegeneration

  2018cites this paper
• Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve

  2018cites this paper
• The Mitochondrial Permeability Transition Pore

  2018cites this paper
• A role for nanor in early zebrafish development and validation of a neurotoxic zebrafish model of Parkinson’s disease

  2018cites this paper
• Release and uptake of pathologic alpha-synuclein

  2018cites this paper
• Dysfunction of mitochondria as the basis of Parkinson’s disease

  2018cites this paper
• Direct Observation of Murine Prion Protein Replication in Vitro

  2018cites this paper
• The concept of alpha-synuclein as a prion-like protein: ten years after

  2018cites this paper
• Sleep disturbances in patients with Parkinson’s disease: It’s time to wake up!

  2018cites this paper
• Prion-like propagation of pathology in Parkinson disease.

  2018cites this paper
• Age-dependent alpha-synuclein accumulation is correlated with elevation of mitochondrial TRPC3 in the brains of monkeys and mice

  2017influential citation
• Hypothesis of Ascension in Idiopathic Parkinson’s Disease

  2017cites this paper
• Gastrointestinal Symptoms and Olfactory Disorder as Prodromal Non-motor Symp- toms of Idiopathic Parkinson’s Disease

  2017cites this paper
• A reaction-diffusion model for the progression of Parkinson's disease

  2017cites this paper
• Prying into the Prion Hypothesis for Parkinson's Disease

  2017cites this paper
• Aszensionshypothese beim idiopathischen Parkinson-Syndrom

  2017cites this paper
• Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.

  2017cites this paper
• Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.

  2017cites this paper
• Gastrointestinal Symptoms and Olfactory Disorder as Prodromal Non-motor Symptoms of Idiopathic Parkinson’s Disease compa-Hypothesis of Ascension in Idiopathic Parkinson ’ s Disease

  2017cites this paper
• Endocytic Vesicle Rupture in the Pathogenesis and Propagation of Neurodegenerative Proteinopathies

  2017cites this paper
• Proteolysis of α‐synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology

  2017cites this paper
• Biomarkers in Parkinson's disease and related disorders. Diagnostic value of biochemical markers and their relation to disease progression

  2017cites this paper
• Disease Primers PARKINSON DISEASE

  2017cites this paper
• Aggregation of alpha-synuclein using single-molecule spectroscopy

  2017cites this paper
• Conformation-Specific Detection of α-Synuclein: The Search for a Biomarker in Parkinson Disease.

  2017cites this paper
• Analysis of sheep α-synuclein provides a molecular strategy for the reduction of fibrillation.

  2017cites this paper
• Gastrointestinal Symptoms and Olfactory Disorder as Prodromal Non-motor Symptoms of Idiopathic Parkinson’s Disease compa-Hypothesis of Ascension in Idiopathic Parkinson ’ s Disease

  2017cites this paper
• Neurodegeneration and RNA‐binding proteins

  2017cites this paper
• Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to &agr;‐synuclein targeted disease modification

  2017cites this paper
• Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1).

  2017cites this paper